[May 14, 2013]

Research and Markets: Rebif (Multiple Sclerosis) - Forecast and Market Analysis to 2022

Research and Markets (http://www.researchandmarkets.com/research/d9c4rv/rebif_multiple) has announced the addition of the "Rebif (Multiple Sclerosis) - Forecast and Market Analysis to 2022" report to their offering.

GlobalData has released its new PharmaPoint Drug Evaluation report, Rebif (Multiple Sclerosis) - Forecast and Market Analysis to 2022. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT (News - Alert)).

The dominance of first-line injectable DMTs, including the interferon beta (IFNß) agents: Bayer's Betaseron/Betaferon (IFNß-1b), Biogens Avonex (IFNß-1a) and Merck's Rebif (IFNß-1a), and Teva's Copaxone (glatiramer acetate), has been a salient feature of the MS therapeutics market. However, the competitive landscape is undergoing significant change with the emergence of oral therapies, several pipeline products with notable efficacies, and looming generics/biosimilars following the patent expiries of key branded products during the forecast period. In addition, the entry of new companies such as Sanofi/Genzyme and F. Hoffmann-La-Roche/Genentech will challenge the position of the established players in the MS marketplace.

Rebif (interferon beta-1a; Merck Serono [EMD Serono in the US]) is an SC-administered, interferon-based DMT that is indicated for the treatment of patients with RRMS and CIS. The drug is co-promoted in the US by EMD Serono and Pfizer. Similar to Avonex, Rebif is produced from genetically engineered CHO cells using recombinant DNA technology, and the 166 amino acid sequence of Rebif is identical to that of natural fibroblast-derived human IFNß (Rebif package insert, 2003). As with the other currently approved interferon agents, the exact mechanism of action of Rebif in MS is not fully elucidated.

Key Topics Covered:

1 List of Tables and Figures

2 Introduction

3 Disease Overview

4 Disease Management

5 Competitive Assessment

6 Rebif (interferon beta-1a)

7 Appendix

For more information visit http://www.researchandmarkets.com/research/d9c4rv/rebif_multiple

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

[ Back To TMCnet.com's Homepage ]